BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.

Abstract

Purpose: Neoadjuvant systemic therapy (NAC) is currently used in the treatment of stage II/III breast cancer. Pathological complete response as a surrogate endpoint for clinical outcomes is not completely validated for all subgroups of breast cancers. Therefore, there is a need for reliable predictive tests of the most effective treatment.

Methods: We used a combination of predictive clinical, pathological, and gene expression-based markers of response to NAC in a prospective phase II multicentre randomized clinical trial in breast cancer patients, with a long follow-up (8 years). This study concerned the subpopulation of 188 patients with similar levels of pathological response rates to sequential epirubicin/cyclophosphamide and docetaxel to determine predictive marker of pCR and DFS. We used a set of 45 genes selected from high throughput analysis and a standardized RT-qPCR. We analyzed the predictive markers of pathological complete response (pCR) and DFS in the overall population and DFS the subpopulation of 159 patients with no pCR.

Results: In the overall population, combining both clinical and genomic variables, large tumor size, low TFF1, and MYBL2 overexpression were significantly associated with pCR. T4 Stage, lymphovascular invasion, negative PR status, histological type, and high values of CCNB1 were associated with DFS. In the no pCR population, only lymphovascular invasion and high values of BIRC5 were associated with DFS.

Conclusions: We confirm the importance of ER-related and proliferation genes in the prediction of pCR in NAC-treated breast cancer patients. Furthermore, we identified BIRC5 (survivin) as a main pejorative prognostic factor in patients with breast cancers with no pCR. These results also open perspective for predictive markers of new targeted therapies.

Keywords: BIRC5; Breast cancer; Neoadjuvant chemotherapy; Predictive.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology
  • Cell Cycle Proteins / genetics
  • Clinical Trials, Phase II as Topic
  • Cyclophosphamide / therapeutic use
  • Docetaxel
  • Epirubicin / therapeutic use
  • Female
  • Humans
  • Inhibitor of Apoptosis Proteins / genetics*
  • Middle Aged
  • Multicenter Studies as Topic
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Prognosis
  • Survivin
  • Taxoids / therapeutic use
  • Trans-Activators / genetics
  • Treatment Outcome
  • Trefoil Factor-1

Substances

  • BIRC5 protein, human
  • Biomarkers, Tumor
  • Cell Cycle Proteins
  • Inhibitor of Apoptosis Proteins
  • MYBL2 protein, human
  • Survivin
  • TFF1 protein, human
  • Taxoids
  • Trans-Activators
  • Trefoil Factor-1
  • Docetaxel
  • Epirubicin
  • Cyclophosphamide